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Sarcoidosis is a multisystemic inﬂammatory disorder with cutaneous lesions present in about one-quarter of the patients.
Cutaneous lesions have been classiﬁed as speciﬁc and nonspeciﬁc, depending on the presence of nonnecrotizing epithelial
cell granulomas on histologic studies. The development and progression of speciﬁc cutaneous sarcoidosis involves a complex
interaction between cells of the adaptive immunesystems, notablyT-lymphocytes anddendritic cells. In this paper, we will discuss
the role of T-cells and skin dendritic cells in the development of primary cutaneous sarcoidosis and comment on the potential
antigenic stimuli that may account for the development of the immunologicalresponse. We will further explore the contributions
of selected cytokines to the immunopathologicalprocess. The knowledge of the adaptive immunologicalmechanismsoperative in
cutaneous sarcoidosis may subsequently be useful for identifying prevention and treatment strategies of systemic sarcoidosis.
1.Introduction
Sarcoidosisis a multisystemic inﬂammatory disorder charac-
terizedbytheaccumulationofmononuclearphagocyteswith
the formation of nonnecrotizing epithelial cell granulomas.
Multiple organs may be involved, including lungs, mediasti-
nal and peripheral lymph nodes, liver, spleen, skin, eyes, and
parotid glands; central nervous system, heart, upper respir-
atory tract, bones, and joints are less frequently but usually
more severely involved [1, 2].
Sarcoidosis is characterized by local immune hyperacti-
vation associated with clinical anergy [3]. The pathogenesis
ofsarcoidosisissuspectedtobeahostimmunologicresponse
to an antigenic exposure [4]. The role of T-lymphocytes in
the recognition of speciﬁc antigens and in the ampliﬁcation
of inﬂammatory responses has been well established [5]. In
addition, dendritic cells have recently been shown to have
a prominent role in the immunopathological processes op-
erating in this condition [6, 7].
Cutaneous involvement in sarcoidosis occurs in about
one-quarter of the patients and is generally observed at the
onset of the disease process although it may occur coincident
with or after systemic involvement [8, 9]. Therefore, cuta-
neous lesions can be an initial presentation and are probably
an important factor in the investigation of the etiology of
sarcoidosis.
Skin lesions may be classiﬁed in speciﬁc, when histology
shows typicalnoncaseating granulomatous inﬂammation, or
non speciﬁc, in presence of reactive process without granu-
lomas.
2.ClinicalAspectsof Primary
CutaneousSarcoidosis
The frequency of speciﬁc skin involvement ranges from
9% to 37% [10]. All speciﬁc cutaneous lesions exhibit non-
caseating granulomas on biopsy. Histological ﬁndings in
speciﬁc sarcoid lesions show aggregates of epithelioid histi-
ocytes with occasional Langhans giant cells and few or no
other inﬂammatory cells, the so-called naked or sarcoidal
noncaseating granulomas. Frequently, there are inclusion
bodies in giant cells [11]. The centre of granulomas is
typically surrounded by CD4+ lymphocytes, rare CD8+
lymphocytes and mature macrophages. Despite the same
histologic appearance, clinical manifestations of primary
cutaneous sarcoidosis may be variable.2 Clinical and Developmental Immunology
The most common types of speciﬁc skin manifestations
are maculopapular lesions. They commonly appear on the
face with a purple or red-brown appearance but may also be
observed on lips, neck, upper trunk, extremities, and rarely
mouth; these lesions show typical apple-jelly colour when
examined by diascopy [10].
Plaques are larger, red-brown, inﬁltrated lesions that
are present on face, scalp, shoulders, arms, and buttocks.
The lesions may be single or multiple and are associated
with chronic course of disease. When plaques are multiple,
distribution of the lesions tends to be symmetric. They may
be associated with large telangiectatic vessels or may exhibit
thick scaling [12].
Speciﬁc cutaneous lesions of sarcoidosis may take form
of mobil and indolent subcutaneous nodules that appear
generally late in the course of the disease. The patients
may present single or multiple nodules with a diameter
between 0.5 and 2cm without clinical alteration of the epi-
dermal compartment. These nodules may be associated with
sarcoidal involvement of lung, spleen, and liver [13].
Scar sarcoidosis is characterised by the development of
red-purple inﬁltrated lesions at the site of previous scar; this
phenomenon, of unknown etiology, may preced the onset
of lung involvement or be simultaneously with systemic
sarcoidosis [14].
Lupus pernio is characterized by an indolent, inﬁltrated
red-brown or purple shiny plaque on nose, lips, cheeks, and
ears, more frequent in African American women. Lupus
pernio can be followed or be associated with chronic ﬁbrotic
disease, notably chronic ﬁbrotic sarcoidosis of upperrespira-
tory tract, lung ﬁbrosis, chronic uveitis, and bone cystis [15].
3.Kveim-SiltzbachReaction:AnImmunological
Model ofPrimaryCutaneousSarcoidosis
The immunopathogenesis of primary cutaneous sarcoidosis
has been studied by means of the Kveim-Siltzbach reaction.
This is an accepted immunological model of sarcoidosis
which is consistent with the hypothesis that this condition
is determined by an ampliﬁed adaptive immune response to
an exogenous antigen at sites of granuloma formation [16].
The Kveim-Siltzbach test consists of an intradermal injection
of a suspension of human sarcoid tissue prepared from
spleen and lymph node which leads to granuloma formation
virtually identical to that of primary cutaneous sarcoidosis
[17]. In contrast to a delayed-type hypersensitivity reaction,
the development of a papular lesion at the injection site is
observed 3 to 6 weeks later. This lesion shows histological
changes of typical noncaseating granulomatous inﬂamma-
tion [16]. This method of testing has been abandoned, but
the several studies carried out on this peculiar skin reaction
have allowed a better understanding of disease pathogenesis.
In particular, Kataria and Park studied the Kveim-Siltzbach
test using sequential biopsies at varying intervals in the
site of reaction [18] .A f t e r6h o u r sf r o mt h ei n t r a d e r m a l
injection, necrotic collagen associated with a perivascular
inﬁltratemainly composedofCD4+T-lymphocytescouldbe
observed. After 48 hours an increased number of monocyte
was observed; subsequently, these cells tended to disappear
probably after transformation into multinucleated giant cells
and epithelioid cells. From day 12 to day 34, lymphocyte
CD4+ T-cells continued to increase whereas the ﬁrst Lang-
hans giant cells were seen on day 12. Biopsy specimens taken
onday21,day 28,and day34demonstrated progressive inﬁl-
tration of T-lymphocytes whereas B cells, monocytes, and
immunoglobulindepositionwerevirtuallyabsent[18].Ithas
been suggested that initial collagen necrosis is responsible of
immobilisation of the putative antigen which may promote
the development of sarcoid granulomas. The initial inﬂux of
lymphocytesand monocytes observedin sarcoidgranulomas
supports the hypothesis that antigen presentation is the
initiating stimulus for granuloma formation [19]. The lack
of a signiﬁcant presence of B lymphocytes in the inﬁltrate of
cutaneous sarcoidosis has been recently conﬁrmed [20]a n d
may support the view that the granulomatous inﬂammation
observed in cutaneous sarcoidosis is essentially a cell-me-
diated process against an unknown antigen encountered
through the epidermis [21]. However, a role of B cells
activated byhelperT-cells maynotcompletelybeexcludedin
light of the apparent therapeutic beneﬁts of B cell depleting
therapy in sarcoidosis [22].
4.DendriticCellsinPrimary
CutaneousSarcoidosis
The Kveim-Siltzbach reaction is consistent with the view that
in cutaneous sarcoidosis the antigen seems to pass through
the epidermis. In support of this hypothesis, there are the
recent ﬁndings concerning the distribution of dendritic cells
in cutaneous sarcoidosis.
Immune cells of the epidermis and dermis participate
in the defense against pathogens, in particular through a
network of cutaneous dendritic cells, which have a key role
in initiating both innate and adaptive immune responses
[23]. Two main populations of dendritic cells occur in
normal skin: epidermal Langerhans cells (LCs) and dermal
dendritic cells. LCs are involved in monitoring the epidermal
microenvironment by taking up antigen and processing
it into fragments that can be recognized by naive and
eﬀectors cells of the adaptive immune response. LCs are
capable of antigen uptake and processing, but at this stage
of diﬀerentiation they are unable to stimulate naive T-cells
and therefore, are considered immature antigen presenting
cells. After capture and antigen-processing LCs migrate out
of the epidermis and “mature” their ability for acting as
professional antigen presenting cells [24]. Dermal dendritic
cells are mature antigen presenting cells which share several
functional andphenotypiccharacteristics with LCsincluding
the ability to activate both naive and eﬀector T-cells [25].
It has been demonstrated an increased number of epi-
dermal LCs in primary cutaneoussarcoidosis [25]. This phe-
nomenon is particularly evident in the epidermis overlying
sarcoidal granulomas and is probably related to the ability of
these cells to capture an environmental antigens through the
epidermal compartment [26]. Furthermore, a maturation
step of LCs has been demonstrated in the subepidermalClinical and Developmental Immunology 3
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Figure 1: The basic immunopathologicalmechanisms that can be expected to be operative in primary cutaneous sarcoidosis.
layer over the cutaneous sarcoid granuloma suggesting that
immature LCs might migrate in the epidermis, where they
become mature antigen presenting cells for T-lymphocytes
[26]. In support of this hypothesis, there is the demonstra-
tion that mature dendritic cells are increased in cutaneous
sarcoidosis and observed around the granuloma attached to
T-lymphocytes [26].
The proposed immunological pathway (Figure 1)m a y
also represent a potential mechanism for explaining systemic
involvement following primary cutaneous sarcoidosis. In
this context, an exogenous antigen penetrated through the
skin is captured and processed by immature Langerhans
cells. The subsequent systemic involvement of sarcoidosis
couldbe determinedby thespread through lymphatic vessels
of antigen-bearing mature dendritic cells. This concept is
supported by the clinical observation that speciﬁc cutaneous
lesions in the course of sarcoidosis are generally observed
before the onset of systemic disease [9].
5.AdaptiveImmune Response inResponseto
a SpeciﬁcAntigeninPrimarySarcoidosis
The nature of the antigens captured through the epider-
mis by LCs is unknown. Identiﬁcation of these antigens
would have importance for our understanding of cutaneous
sarcoidosis and, possibly, cutaneous and systemic disease
prevention.
The speciﬁcity of the adaptive immune response resides
in the antigen receptors on T and B cells [27]. These
receptors are the results of a gene rearrangement process
during lymphocyte maturation. The receptors produced by
each lymphocyte have a unique antigen speciﬁcity which is
determined by the structure of antigen binding site. This
ensures that the receptor on each lymphocyte is single and
speciﬁc. As a consequence, the adaptive immune response
against a particular antigen is characterized by the initial
stimulation of only a very small proportion of lymphocytes
whose surface antigen receptors are able to recognize the
speciﬁc antigen. The resulting antigen-driven proliferation
results in the generation of large numbers of lymphocytes
bearing the same antigen receptor and, consequently, the
same antigen speciﬁcity [27].
It has been hypothesized that antigen speciﬁc T-cell
clones are responsible for the onset and maintenance of
cutaneous sarcoidosis [28]. In order to evaluate whether
speciﬁc antigen-driven T-cell responses are involved in
the initiation and/or maintenance of cutaneous sarcoido-
sis, it is necessary to examine whether T-cells inﬁltrating4 Clinical and Developmental Immunology
cutaneous sarcoid granulomas contain expanded clones of
T-cells. Characterization of the transcripts of T-cell antigen
receptor genes can be used to determine the clonality of T-
lymphocytes populations inﬁltrating cutaneous sarcoidosis
and may allow determination of their antigen speciﬁcity.
These antigens may play a key role in the pathogenesis
of cutaneous sarcoidosis. To this regard, an oligoclonal
expansion of T-cells with a preferential expression of antigen
T-cell receptor genes has been demonstrated at sites of
Kveim-Siltzbachskinreactionsgivingevidenceofanantigen-
driven T-cell immune response [29]. A similar phenomenon
was observed in patients with primary cutaneous sarcoidosis
where anantigen-drivenoligoclonalexpansion of T-cells was
detected [30]. However, the T-cell receptor gene usage in T-
cell clones from patients with primary cutaneous sarcoidosis
showed interindividual variability, thus indicating that the
inappropriate response observed in cutaneous sarcoidosis is
probably not determined by a common antigenic stimulus,
but it may be the result of an individual predisposition in
responding to a variety of self/nonself antigens [30].
6.The RoleofCytokinesin
CutaneousSarcoidosis
Cytokines are extracellular signalling proteins that mediate
the eﬀector functions of a variety of inﬂammatory cells. In
particular, cytokine secretion by T lymphocytes has a key
role in the adaptive immune responses against pathogens
and/or autoantigens. On the basis of cytokine secretion,
T helper (Th) lymphocytes are divided into at least two
distinct subsets: type 1 helper T-cells (Th1 cells) and type 2
helper T-cells (Th2 cells). Th1 cells produce cytokines which
mediate cell-mediated immunity, while cytokines produced
by Th2 cells are associated with helper function for anti-
body production by B cells. Th1 cells are characterized by
the production of interferons, tumor-necrosis factors, and
interleukin-2, whereas a Th2 cytokine proﬁle is associated
with production of IL-4, IL-5, IL-6, IL-9, and IL-10 [31].
A Th1 predominant proﬁle of cytokine production has
been observed in systemic sarcoidosis, where only low levels
of Th2-associated mediators have been detected [32, 33]. It
is likely that a similar cytokine imbalance may be responsible
for the onset and/or maintenance of cutaneous sarcoidosis.
Although to date no studies have investigated the expression
of these cytokines in cutaneous sarcoidosis, there is clinical
evidenceindicating a role for some cytokinesassociated with
a Th1 immune response, notably interferon (IFN) alpha and
tumor necrosis factor (TNF) alpha.
Interferons are proinﬂammatory cytokines divided into
two main classes: type I IFN such as IFN-alpha and type II
IFN, notably IFN-gamma, both of which function as a
bridge linking innate and adaptive immune responses and
are responsible in shaping the subsequent development of
adaptive immunity [34]. To this regard, several lines of
evidence support the importance of IFN-alpha in regulation
of the Th1 subset diﬀerentiation [35]. IFN-alpha, as other
interferons, has antiviral and antioncogenic eﬀects and, in
combinationwithribavirin, hasbecomethecurrentstandard
therapy for treating chronic hepatitis C patients [36]. The
d e v e l o p m e n to fp r i m a r yc u t a n e o u sa sw e l la ss y s t e m i c
sarcoidosis has been well-documented in chronic hepatitis
C patients treated with IFN-alpha [37–41]. Furthermore,
cutaneous sarcoidosis has also been observed during IFN-
alpha based therapy for melanoma [42–44]. IFN-alpha
induces T-cells to produce large amounts of Th1 cytokines
and limited amounts of Th2 cytokines, favouring the de-
velopment and enhancement of Th1-mediated responses.
In particular, IFN-alpha induces STAT1 expression, a Th1
transcription factor that regulates several genes involved in
the inﬂammatory response [45]. In this regard, a recent
investigation has demonstrated increased STAT1 expression
in sarcoidosis granulomas [46]. Taken together these data
are consistent with the view that the enhancement of cell-
mediated immunity by IFN-alphain thepresence ofan as yet
unknown cutaneous antigenic stimulus may be responsible
for the development of cutaneous sarcoidosis in patients
treated with this biological agent.
TNF-alpha is a pro-inﬂammatory cytokine that plays a
signiﬁcant role in antigen-stimulated cell-mediated immune
responses and in the development of Th1 responses [47].
In sarcoidosis, TNF-alpha participates in the induction and
maintenance of granulomas and high levels of TNF-alpha
seems to correlate with systemic disease progression [48].
There is clinical evidence that inhibition of TNF-alpha is an
eﬀective therapy for treating both systemic and cutaneous
sarcoidosis which is consistent the view that TNF-alpha
plays a prominent role in the inﬂammatory process seen
in these conditions [49–53]. On the other hand, anti-TNF-
alpha therapies can induce sarcoidosis, including primary
cutaneous sarcoidosis [54, 55]. This may be determined by
a paradoxical enhanced Th1 response with alteration of
the cutaneous cytokine environment and enhancement of
inﬂammatory cell inﬁltration into the skin. In particular, a
cross-regulation betweenIFN-alphaandTNF-alphahasbeen
recently proposed, where both cytokines may interact each
other to aﬀect the inﬂammatory responses [56]. According
to this hypothesis, the paradoxical adverse eﬀects of anti-
TNF-alpha treatment, such as the exacerbation of psoriatic
skin lesions in patients with psoriatic arthritis receiving anti-
TNF-alpha therapy, can be considered as a consequence of
t h ed i s b a l a n c eb e t w e e nt h et w oc y t o k i n e s .I nt h i sr e g a r d ,
it has been demonstrated that patients treated with TNF
antagonists demonstrate upregulation of IFN-α-responsive
genes [57]. The development of cutaneous sarcoidosis after
TNF-blockerstherapymayprobablybetriggeredbyaninitial
exposure to a skin antigen and it has been suggested that
Propionibacterium acnes may promote the skin immune
response observed in sarcoidosis [58]. Furthermore, TNF
blockersincrease theriskofinfectiouscomplications,includ-
ing Propionibacterium acnes infection [59]. Taken together,
these observations are consistent with the hypothesis, that
both increased risk of skin infections and alterations in the
skin immunological microenvironment may be responsible
for the paradoxical occurrence of cutaneous sarcoidosis
during treatment with TNF-blockers.
Interleukin-17 (IL17) is a proinﬂammatory cytokine
that is involved in the pathogenesis of several chronicClinical and Developmental Immunology 5
inﬂammatory diseases by upregulating the expression of
various cytokines, chemokines, and cell-adhesion molecules
[60].T-helper17(Th17)cellsarearecentlydiscoveredsubset
of CD4(+) helper T-cell that release large amounts of IL17
[60]. It has been demonstrated that this cytokine is involved
in the alveolitic/granuloma phase of the disease and it seems
plausible that it may also play a role in cutaneous granuloma
formation [61].
7.Conclusions
Cutaneous sarcoidosis is a primary skin disorder with
a poorly understood pathophysiologic mechanism. CD4+
lymphocytes and cutaneous dendritic cells probably rep-
resent the predominant cellular elements involved in the
inﬂammatory responses. The adaptive immune system
appears to actively participate in disease development and
maintenance by elaboration of Th1 cytokines. Identiﬁcation
of the antigen(s) responsible for the adaptive immune acti-
vation may represent an important step in the recognition of
the immunopathological mechanism operating in cutaneous
sarcoidosis. The knowledge of the adaptive immunological
mechanisms operative in cutaneous sarcoidosis may subse-
quently be useful for identifying prevention and treatment
strategies for systemic sarcoidosis.
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